Plain-English translation of NCT04667078 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a fast-acting blood-thinning medication, can improve outcomes when given alongside emergency clot removal surgery (called mechanical thrombectomy) for acute stroke. Even after successful clot removal, many stroke patients don't fully recover because blood flow to the brain remains partially blocked. This medication might help restore more complete blood flow and reduce disability.
Today, more than half of stroke patients treated with clot removal surgery remain disabled after 3 months, often because blood flow to the brain isn't fully restored. This medication has been shown to work well in similar heart conditions, and researchers believe it might help more stroke patients achieve better blood flow and better recovery.
If you qualify and join this trial, you will be randomly assigned to receive either clot removal surgery alone with standard care, or clot removal surgery plus the new blood-thinning medication given through an IV. The medication would be started right before your surgery and continued during the procedure (up to 4 hours). After that, you would transition to oral blood-thinning medications as standard. Your recovery would be monitored using standard follow-up care.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
France